company background image
ONCT

Oncternal Therapeutics NasdaqCM:ONCT Stock Report

Last Price

US$0.92

Market Cap

US$51.8m

7D

-1.6%

1Y

-67.9%

Updated

01 Dec, 2022

Data

Company Financials +
ONCT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ONCT Stock Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.

Oncternal Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncternal Therapeutics
Historical stock prices
Current Share PriceUS$0.92
52 Week HighUS$3.02
52 Week LowUS$0.69
Beta1.44
1 Month Change-12.38%
3 Month Change-16.36%
1 Year Change-67.94%
3 Year Change-82.58%
5 Year Changen/a
Change since IPO-86.91%

Recent News & Updates

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Recent updates

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01
Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Shareholder Returns

ONCTUS BiotechsUS Market
7D-1.6%2.7%1.4%
1Y-67.9%-10.3%-16.1%

Return vs Industry: ONCT underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: ONCT underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is ONCT's price volatile compared to industry and market?
ONCT volatility
ONCT Average Weekly Movement8.8%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: ONCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ONCT's weekly volatility has decreased from 16% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a28Jim Breitmeyerhttps://www.oncternal.com

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics, Inc. Fundamentals Summary

How do Oncternal Therapeutics's earnings and revenue compare to its market cap?
ONCT fundamental statistics
Market CapUS$51.83m
Earnings (TTM)-US$40.84m
Revenue (TTM)US$1.88m

27.6x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ONCT income statement (TTM)
RevenueUS$1.88m
Cost of RevenueUS$21.88m
Gross Profit-US$20.00m
Other ExpensesUS$20.84m
Earnings-US$40.84m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.72
Gross Margin-1,066.93%
Net Profit Margin-2,178.29%
Debt/Equity Ratio0%

How did ONCT perform over the long term?

See historical performance and comparison